Karyopharm Therapeutics Inc.
KPTI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $145,237 | $146,033 | $157,074 | $209,819 |
| % Growth | -0.5% | -7% | -25.1% | – |
| Cost of Goods Sold | $6,007 | $4,942 | $5,213 | $3,402 |
| Gross Profit | $139,230 | $141,091 | $151,861 | $206,417 |
| % Margin | 95.9% | 96.6% | 96.7% | 98.4% |
| R&D Expenses | $143,232 | $138,750 | $148,662 | $160,842 |
| G&A Expenses | $115,441 | $131,881 | $145,401 | $143,846 |
| SG&A Expenses | $115,441 | $131,881 | $145,401 | $143,846 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $258,673 | $270,631 | $294,063 | $304,688 |
| Operating Income | -$119,443 | -$129,540 | -$142,202 | -$98,271 |
| % Margin | -82.2% | -88.7% | -90.5% | -46.8% |
| Other Income/Exp. Net | $43,078 | -$13,236 | -$22,720 | -$25,549 |
| Pre-Tax Income | -$76,365 | -$142,776 | -$164,922 | -$123,820 |
| Tax Expense | $57 | $323 | $369 | $268 |
| Net Income | -$76,422 | -$143,099 | -$165,291 | -$124,088 |
| % Margin | -52.6% | -98% | -105.2% | -59.1% |
| EPS | -9.41 | -18.79 | -30.28 | -24.75 |
| % Growth | 49.9% | 37.9% | -22.3% | – |
| EPS Diluted | -9.41 | -18.79 | -30.28 | -24.75 |
| Weighted Avg Shares Out | 8,124 | 7,615 | 5,458 | 5,015 |
| Weighted Avg Shares Out Dil | 8,124 | 7,615 | 5,458 | 5,015 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,400 | $10,943 | $2,359 | $582 |
| Interest Expense | $37,422 | $23,823 | $24,996 | $26,046 |
| Depreciation & Amortization | $340 | $530 | $621 | $789 |
| EBITDA | -$38,603 | -$118,423 | -$139,305 | -$96,985 |
| % Margin | -26.6% | -81.1% | -88.7% | -46.2% |